Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) Gross Profit (2019 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Gross Profit for 7 consecutive years, with $13.1 million as the latest value for Q4 2025.

  • Quarterly Gross Profit rose 102.29% to $13.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $42.7 million through Dec 2025, up 82.56% year-over-year, with the annual reading at $42.7 million for FY2025, 82.56% up from the prior year.
  • Gross Profit hit $13.1 million in Q4 2025 for Eton Pharmaceuticals, up from $7.9 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $13.1 million in Q4 2025 to a low of $121000.0 in Q3 2021.
  • Historically, Gross Profit has averaged $6.0 million across 5 years, with a median of $5.7 million in 2021.
  • Biggest five-year swings in Gross Profit: soared 343666.67% in 2021 and later crashed 87.13% in 2022.
  • Year by year, Gross Profit stood at $5.7 million in 2021, then grew by 11.17% to $6.4 million in 2022, then crashed by 42.92% to $3.6 million in 2023, then soared by 78.4% to $6.5 million in 2024, then surged by 102.29% to $13.1 million in 2025.
  • Business Quant data shows Gross Profit for ETON at $13.1 million in Q4 2025, $7.9 million in Q3 2025, and $11.9 million in Q2 2025.